Src Tyrosine-Protein Kinase: Potential Drug Target Or Biomarker

Target Name: Tyrosine-Protein Kinases Src

NCBI ID: P38634

Tyrosine-Protein Kinases Src

Other Name(s): Tyrosine-Protein Kinase Src | Src family kinase | SFK

Src Tyrosine-Protein Kinase: Potential Drug Target Or Biomarker

Tyrosine-protein kinases (TPKs) are a family of enzymes that play a crucial role in cell signaling and metabolism. The Src (nonspecified subtype) tyrosine-protein kinase is a member of this family and has been identified as a potential drug target or biomarker.

The Src tyrosine-protein kinase is a protein that is expressed in a variety of tissues and cells, including muscle, nerve, and heart cells. It is a potent tyrosine-protein kinase that is involved in the regulation of a wide range of cellular processes , including cell growth, differentiation, and survival. The Src tyrosine-protein kinase has four known isoforms, which are different in their catalytic specificity and subcellular localization.

The Src tyrosine-protein kinase is involved in many different signaling pathways, including the regulation of cell adhesion, the cytoskeleton, and the cell cycle. It is a key regulator of the T-cell receptor (TCR), which is responsible for cell signaling and immune responses. The Src tyrosine-protein kinase is also involved in the regulation of the production of intracellular signaling molecules, such as mitogen-activated protein kinases (MAPKs) and heat shock proteins (HSPs).

The Src tyrosine-protein kinase has been shown to be a potential drug target by several studies. One study published in the journal Nature Medicine used a small molecule inhibitor to inhibit the Src tyrosine-protein kinase and show that this inhibition inhibited the growth and survival of cancer cells. Another study published in the journal Cell used a similar approach to show that inhibiting the Src tyrosine-protein kinase inhibited the migration and invasion of cancer cells.

In addition to its potential as a drug target, the Src tyrosine-protein kinase is also a potential biomarker for cancer. The Src tyrosine-protein kinase is often overexpressed in cancer cells, which means that the levels of the Src tyrosine-protein kinase are higher than in normal cells. This overexpression can be used as a biomarker for cancer, particularly in the assessment of prognosis and response to treatment.

The Src tyrosine-protein kinase is also involved in the regulation of many different cellular processes, including cell growth, differentiation, and survival. This makes it an attractive target for the development of new therapies. For example, inhibitors of the Src tyrosine-protein Kinases have been shown to be effective in treating a variety of cancers, including breast, ovarian, and colorectal cancers.

In conclusion, the Src (nonspecific subtype) tyrosine-protein kinase is a protein that is involved in a wide range of cellular processes and has been identified as a potential drug target or biomarker. The Src tyrosine-protein kinase is involved in the regulation of cell adhesion, the cytoskeleton, and the cell cycle, as well as the regulation of intracellular signaling molecules. Its potential as a drug target or biomarker makes it an attractive target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of the Src tyrosine-protein kinase in cellular processes and its potential as a drug target or biomarker.

Protein Name: Tyrosine-Protein Kinases Src (nonspecified Subtype)

The "Tyrosine-Protein Kinases Src Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Tyrosine-Protein Kinases Src comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets